Cargando…
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
CONTEXT: Prader-Willi syndrome (PWS) is a rare neurobehavioral-metabolic disease caused by the lack of paternally expressed genes in the chromosome 15q11-q13 region, characterized by hypotonia, neurocognitive problems, behavioral difficulties, endocrinopathies, and hyperphagia resulting in severe ob...
Autores principales: | Miller, Jennifer L, Gevers, Evelien, Bridges, Nicola, Yanovski, Jack A, Salehi, Parisa, Obrynba, Kathryn S, Felner, Eric I, Bird, Lynne M, Shoemaker, Ashley H, Angulo, Moris, Butler, Merlin G, Stevenson, David, Abuzzahab, Jennifer, Barrett, Timothy, Lah, Melissa, Littlejohn, Elizabeth, Mathew, Verghese, Cowen, Neil M, Bhatnagar, Anish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10271219/ https://www.ncbi.nlm.nih.gov/pubmed/36639249 http://dx.doi.org/10.1210/clinem/dgad014 |
Ejemplares similares
-
OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Abuzzahab, Jennifer, et al.
Publicado: (2022) -
RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Woloschak, Michael, et al.
Publicado: (2022) -
A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome
por: Kimonis, Virginia, et al.
Publicado: (2019) -
Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020) -
Prader-Willi syndrome: A primer for clinicians
por: Cataletto, Mary, et al.
Publicado: (2011)